The fda is preparing to put warning labels on epilepsy drugs, including topiramate marketed as topamax , valproate marketed as depakote, depakote er, depakene, depacon , pregabalin marketed as lyrica , and zonisamide marketed as zonegran that will notify users about the increased risk for suicidal behavior.